A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia

By T. Borsello, P. Clarke, L. Hirt, Alessandro Vercelli, M. Repici, D. Schorderet, J. Bogousslavsky, C. Bonny. Nature Medicine, 2003

709 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/4d4744b5520d426458731d38abeadc63eec082ae

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. R. Ji
2. Eng H. Lo
3. M. Malcangio
4. Clifford J. Woolf

In Molecular Biology

1. A. Nebreda
2. Ji-Hong Hong
3. R. Ji
4. Jeroen Essers
5. Kum Khanna
6. J. Campisi
7. Andy Chi-Lung Lee
8. J. Harris

Citations in the corpus

• A Comprehensive Review on Current Advances in Peptide Drug Development and Design (2019, background): “Brimapitide is under a phase III trial [68,69].”
• A new penumbra: transitioning from injury into repair after stroke (2008, background): “Inhibitors can be effectively administered even up to six hours after stroke onse”
• Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging (2017, background): “Modification of peptides to such a D-retro inverso (DRI)-isoform can render peptides new chemical properties, which may improve their potency in vitro and in vivo (Borsello et al., 2003).”
• Reactive Oxygen Species-Induced Activation of the MAP Kinase Signaling Pathways (2006, neutral): “In fact, signaling via the p38 pathway may actually inhibit phosphorylation by other MAPK pathway, may be the reason that transfection with RAS can lead to or augment apoptosis in some cases (54, 168, 173).”
• Cell-Penetrating Peptides: From Basic Research to Clinics. (2017, background): “TAT–[703_TD$DIFF]JBD20 (D-JNKI-1) MCAO in mice Cerebral ischemia [92]”
• MAP kinase and pain (2008, background): “D-JNKI-1 is a very potent inhibitor of JNK and shows great efficacy in an animal model of naturopathic pain (Zhuang et al., 2006) and in patients with acute acoustic trauma (Suckfuell et al., 2007).”
• Signal integration by JNK and p38 MAPK pathways in cancer development (2009, background): “However, several peptide inhibitors have been developed, such as JNKI1 (Ref”
• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate (2006, background): “Treatment of cells with a selective inhibitor of JNK activity, the JNK inhibitor peptid”
• Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. (2010, background): “The peptide has been shown to protect in stroke models as well as in isolated perfused hearts and in vivo (47, 273, 430).”
• Excitotoxicity and stroke: identifying novel targets for neuroprotection. (2014, neutral): “Tat protein (Barr et al., 2002; Bonny et al., 2001; Borsello et al., 2003).”